REG - Oxford Biomedica PLC - Block Listing Application

Oxford BioMedicaAnnouncement

Thu 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250605:nRSE4945La&default-theme=true

RNS Number : 4945L  Oxford Biomedica PLC  05 June 2025

 

OXB

Block Listing Application

Oxford, UK - 05 June 2025: OXB (LSE: OXB), a gobal quality and innovation-led
cell and gene therapy CDMO, today announces that application has been made to
the Financial Conduct Authority and the London Stock Exchange for admission
(i) to the Equity Shares (Commercial Companies) ("ESCC") category of the
Official List and (ii) to trading on the London Stock Exchange for a block
listing of 250,000 ordinary shares of 50 pence each in the capital of the
company (the "Ordinary Shares"), all of which will be issued from time to time
pursuant to the OXB Long Term Incentive Plan (LTIP).

The Ordinary Shares are being reserved under a block listing and will be
issued from time to time pursuant to the following schemes:

 

·      OXB Long Term Incentive Plan (LTIP) (250,000 Ordinary Shares).

 

It is expected that admission to the Official List and the London Stock
Exchange of the New Ordinary Shares will become effective on 10 June 2025. The
New Ordinary Shares will rank pari passu in all respects with the Company's
existing ordinary shares in issue.

 

-Ends-

 

 Enquiries:

 Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
 (mailto:cosec@oxb.com)

 ICR Healthcare:

 T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
 (mailto:oxb@icrhealthcare.com)

 Mary-Jane Elliott / Angela Gray / Davide Salvi

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities span
from early stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSQZLFBEQLLBBK